Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1267-1274

  Yamazaki, Shinji ^a   Skaptason, Judith ^a   Romero, David ^a   Lee, Joseph H ^a   Zou, Helen Y ^a   Christensen, James G ^a   Koup, Jeffrey R ^a   Smith, Bill J ^a   Koudriakova, Tatiana ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; BIOLOGICAL MARKER; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; GLIOBLASTOMA; MATHEMATICAL MODEL; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; TANDEM MASS SPECTROMETRY; TRANSPLANTATION, HETEROLOGOUS;

MUS; PHOS;

EID: 46449090520     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019711     Document Type: Article

References (23)

1. Beal SL and Sheiner LB (1992) NONMEM User Guides, University of California at San Francisco, San Francisco, NONMEM Project Group.
2. Bellusci S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP, and Jouanneau J (1994) Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9:1091-1099.
3. Birchmeier C, Birchmeier W, Gherardi E, and Vande Wound GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-9125.
4. Bissery MC, Vrignaud P, Lavelle F, and Chabot GG (1996) Experimental antitumor activity and pharmacokinetics of camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7:437-460.
5. Chien JY, Friedrich S, Heathman MA, de Alwis DP, and Sinha V (2005) Pharmaeokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:E544-E559.
6. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
7. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, and Venitz J (2000) Pharmaeokinetie/pharrnacodynamic modeljng in drug research and development. J Clin Pharmacol 40:1399-1418.
8. Efron B and Tibshirani R (1993) An Introduction to the Bootstrap, London, Chapman & Hall.
9. Gompertz B (1825) On the nature of the function expressive of the law of human mortality, and on the new mode of determining the value of life contingencies. Phil Trans R Soc Lond 115:513-585.
10. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, and Vande Woude GF (1997) Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94:11445-11450.
11. Jusko WJ and Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
12. Jusko WJ, Ko HC, and Ebling WF (1995) Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 23:5-8.
13. Lesko LJ, Rowland M, Peck CC, and Blascheke TF (2000) Optimizing the science of drag development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17:1335-1344.
14. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmaeodynamic models. Drug Metab Dispos 31:510-518.
15. Norton L and Simon R (1977) Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 58:1735-1741.
16. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, and Vande Woude GF (1992) Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12:5152-5158.
17. Rong S, Segal S, Anver M, Resau JH, and Vande Woude GF (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepaloeyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A 91:4731-4735.
18. Sheiner LB (1984) The population approach to pharmacokinedc data analysis: rational and standard data analysis methods. Drug Metab Rev 15:153-171.
19. Sheiner LB, Stanski DR, Vozeh S, Miller RD, and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarinc. Clin Pharmacol Ther 25:358-371.
20. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, and Roechetti M (2004) Predictive pharmacokinefic-pharmacodynarnic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101.
21. van Schaick EA, De Graaf HJMM, IJzerman AP, and Danhof M (1997) Physiological indirect effect modeling of the anti-lipolytic effects of adenosine A1 receptor agonists. J Pharmacokinet Biopharm 25:713-730.
22. Verotta D and Sheiner LB (1995) A general conceptual model for non-steady-state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm 23:1-4.
23. Zou HY, Li Q, Lee J, Arango M, McDonnell SR, Dusell C, Stempniak M, Yamazaki S, Koudriakova T, Alton G, et al. (2007) An orally available small molecule inhibitor of cMet, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and anti-angiogenetic mechanisms. Cancer Res 67:4408-4417.